Long-Term Efficacy and Safety of FINTEPLA in Treating Lennox-Gastaut Syndrome Revealed The final analysis of the open-label study on FINTEPLA demonstrates its long-term efficacy in reducing seizures for Lennox-Gastaut syndrome patients, enhancing their quality of life.

Long-Term Efficacy and Safety of FINTEPLA in Treating Lennox-Gastaut Syndrome Revealed #United_States #Atlanta #UCB #FINTEPLA #Lennox-Gastaut_Syndrome

UCB Showcases Groundbreaking Epilepsy Research at International Epilepsy Congress UCB presents 26 research abstracts at the International Epilepsy Congress, highlighting advancements in epilepsy treatment and patient care with a focus on DEEs.

UCB Showcases Groundbreaking Epilepsy Research at International Epilepsy Congress #UCB #Brussels #Belgium #Epilepsy #FINTEPLA

New Study Confirms Long-Term Safety and Efficacy of FINTEPLA for Dravet Syndrome The final analysis of a long-term study reveals that FINTEPLA offers significant safety and effectiveness in reducing seizures in Dravet syndrome patients.

New Study Confirms Long-Term Safety and Efficacy of FINTEPLA for Dravet Syndrome #United_States #Atlanta #UCB #Dravet_Syndrome #FINTEPLA

UCB's Remarkable Growth in 2024 Showcases Strong Product Launch Performance UCB achieved impressive financial milestones in 2024, achieving significant revenue and net sales growth driven by successful product launches and a robust pipeline.

UCB's Remarkable Growth in 2024 Showcases Strong Product Launch Performance #UCB #Brussels #Belgium #FINTEPLA #BIMZELX

UCB Unveils Critical Insights on Epilepsy at 2024 AES Annual Meeting Explore UCB's pivotal findings on epilepsy's impact and burden at the 2024 American Epilepsy Society meeting, emphasizing women's needs.

UCB Unveils Critical Insights on Epilepsy at 2024 AES Annual Meeting #United_States #Los_Angeles #UCB #Epilepsy #FINTEPLA